Microwave ablation effective treatment option for small renal masses, finds study
UK: Microwave ablation (MWA) is a safe and effective treatment method and can be considered for the management of small renal masses in patients with suspected renal cell carcinoma (RCC), a recent study has found. The results are published in the journal BJU International.
Joseph B. John, The Royal Devon and Exeter NHS Foundation Trust, Exeter, UK, and colleagues reported a tertiary referral centre's experience of microwave ablation (MWA) for suspected renal cell carcinoma, describing complications and oncological outcomes.
For the purpose, the researchers maintained consecutive MWA procedures (n = 113) for renal masses on a prospective database. Data describing patient, disease, procedure, complications, and oncological outcomes were analysed. The median age was 68 years, 73% were male, and the median Charlson Comorbidity Index was 0.
Key findings of the study include:
- The median (interquartile range [IQR]) tumour diameter was 25 mm.
- In all, 95% had renal mass biopsy, with histologically confirmed cancer in 75%.
- The median (IQR) R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness, Anterior/Posterior, Location) nephrometry score was 7 (6–8).
- The median ablation time was 6 min and length of stay was 1 day for 95% of the patients. Clavien–Dindo complication Grades I, II, IIIb and IV occurred in 18%, 1.8%, 0.9% and 0.9%, respectively.
- The median follow‐up was 12 months and the median (IQR) renal function change was −4%.
- 0.9% had local recurrence, treated with re‐ablation; two developed metastatic progression; and 1.8% had indeterminate findings on follow‐up (one lung nodule and one possible local recurrence), managed with ongoing protocolised computed tomography surveillance.
- Post‐procedure complications were associated with total ablation time (odds ratio [OR] 1.152/min) and total ablation energy (OR 1.017/kJ).
"We describe the largest UK series of MWA treatment for T1a/small T1b renal masses to date. MWA was well tolerated, with 95% discharged the following day and low complication/re‐admission rates," wrote the authors. "Current follow‐up demonstrates favourable disease control. MWA appears to be safe and effective and should be considered in future prospective comparisons of treatments for T1a/small T1b renal masses."
Reference:
The study titled, "Percutaneous microwave ablation of renal masses in a UK cohort," is published in the journal BJU International.
DOI: https://bjui-journals.onlinelibrary.wiley.com/doi/abs/10.1111/bju.15224
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.